Rigel Pharmaceuticals, Inc. (RIGL): Price and Financial Metrics

Rigel Pharmaceuticals, Inc. (RIGL): $4.06

-0.02 (-0.49%)

POWR Rating

Component Grades














  • Value is the dimension where RIGL ranks best; there it ranks ahead of 90.36% of US stocks.
  • The strongest trend for RIGL is in Momentum, which has been heading down over the past 31 weeks.
  • RIGL's current lowest rank is in the Stability metric (where it is better than 4.08% of US stocks).

RIGL Stock Summary

  • For RIGL, its debt to operating expenses ratio is greater than that reported by merely 21.52% of US equities we're observing.
  • In terms of twelve month growth in earnings before interest and taxes, Rigel Pharmaceuticals Inc is reporting a growth rate of -70.92%; that's higher than 25.01% of US stocks.
  • Revenue growth over the past 12 months for Rigel Pharmaceuticals Inc comes in at 30.71%, a number that bests 82.88% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Rigel Pharmaceuticals Inc are FLXS, CARS, CHX, HSII, and DHX.
  • Visit RIGL's SEC page to see the company's official filings. To visit the company's web site, go to www.rigel.com.

RIGL Valuation Summary

  • In comparison to the median Healthcare stock, RIGL's price/sales ratio is 56.12% lower, now standing at 5.2.
  • RIGL's price/sales ratio has moved down 16.4 over the prior 243 months.
  • RIGL's price/sales ratio has moved down 16.4 over the prior 243 months.

Below are key valuation metrics over time for RIGL.

Stock Date P/S P/B P/E EV/EBIT
RIGL 2021-03-04 5.6 17.9 -20.5 -21.7
RIGL 2020-03-02 6.1 6.8 -5.4 -5.7
RIGL 2015-11-25 9.9 2.9 -4.6 -4.0
RIGL 2010-01-20 NA 3.7 -4.0 -3.2
RIGL 2008-02-12 87.7 7.2 -9.6 -9.1
RIGL 2004-12-08 80.1 7.5 -8.6 -8.6

RIGL Growth Metrics

  • Its year over year net cashflow from operations growth rate is now at -56.8%.
  • The year over year price growth rate now stands at 77.04%.
  • Its 4 year price growth rate is now at -28.47%.
Over the past 15 months, RIGL's revenue has gone up $74,590,000.

The table below shows RIGL's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-03-31 133.878 -69.047 -11.487
2020-12-31 108.621 -52.185 -29.744
2020-09-30 105.571 -46.262 -27.707
2020-06-30 108.039 -41.421 -25.023
2020-03-31 102.425 -44.034 -28.053
2019-12-31 59.288 -41.51 -66.894

RIGL Price Target

For more insight on analysts targets of RIGL, see our RIGL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $8.50 Average Broker Recommendation 1.33 (Strong Buy)

RIGL Stock Price Chart Interactive Chart >

Price chart for RIGL

RIGL Price/Volume Stats

Current price $4.06 52-week high $5.50
Prev. close $4.08 52-week low $2.14
Day low $3.96 Volume 882,695
Day high $4.12 Avg. volume 2,938,406
50-day MA $4.08 Dividend yield N/A
200-day MA $3.63 Market Cap 690.87M

Rigel Pharmaceuticals, Inc. (RIGL) Company Bio

Rigel Pharmaceuticals, Inc. engages in the discovery and development of small-molecule drugs for the treatment of inflammatory and autoimmune diseases, immuno-oncology related diseases, and muscle disorders. The company was founded in 1996 and is based in South San Francisco, California.

RIGL Latest News Stream

Event/Time News Detail
Loading, please wait...

RIGL Latest Social Stream

Loading social stream, please wait...

View Full RIGL Social Stream

Latest RIGL News From Around the Web

Below are the latest news stories about Rigel Pharmaceuticals Inc that investors may wish to consider to help them evaluate RIGL as an investment opportunity.

3 Biotech Stocks That Could Rocket Higher

Over the past year, these small-cap drugmakers have done well by their shareholders, and more big catalysts could be coming.

Yahoo | July 24, 2021

New TAVALISSE® Data Analyses To Be Presented at International Society on Thrombosis and Haemostasis (ISTH) 2021 Congress

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that data from its clinical development program for TAVALISSE® (fostamatinib disodium hexahydrate) tablets will be highlighted in two presentations at the upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress, taking place online from July 17 – 21, 2021.

Yahoo | July 14, 2021

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL): Can A Stock Thats Up 2.6% YTD Still Be Considered In Loss Territory?

During the last session, Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)s traded shares were 777,538, with the beta value of the company hitting 1.5. At the end of the trading day, the stocks price was $4.41, reflecting an intraday loss of -2% or -$0.09. The 52-week high for the RIGL share is $5.5, that puts it down -24.72% []

Investor Newsletter | July 3, 2021

Fostamatinib Selected for NIH ACTIV-4 COVID-19 Clinical Trial

SOUTH SAN FRANCISCO, Calif., June 29, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that fostamatinib, the Company''s novel oral spleen tyrosine kinase (SYK) inhibitor, has been selected for a National Institutes of Health (NIH) ACTIV-4 (Accelerating

PR Newswire | June 29, 2021

Rigel''s Fostamatinib Selected for NIH ACTIV-4 COVID-19 Trial

Rigel Pharmaceuticals Inc''s (NASDAQ: RIGL ) fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, has been

Business Insider Markets | June 29, 2021

Read More 'RIGL' Stories Here

RIGL Price Returns

1-mo -10.57%
3-mo 7.41%
6-mo 16.67%
1-year 56.15%
3-year 44.48%
5-year 73.50%
YTD 16.00%
2020 63.55%
2019 -6.96%
2018 -40.72%
2017 63.03%
2016 -21.45%

Continue Researching RIGL

Here are a few links from around the web to help you further your research on Rigel Pharmaceuticals Inc's stock as an investment opportunity:

Rigel Pharmaceuticals Inc (RIGL) Stock Price | Nasdaq
Rigel Pharmaceuticals Inc (RIGL) Stock Quote, History and News - Yahoo Finance
Rigel Pharmaceuticals Inc (RIGL) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.9816 seconds.